Randox employee hosts bake sale in aid of the Cystic Fibrosis Trust
Randox employees enjoyed a bake sale yesterday at our headquarters in Crumlin. The bake sale was hosted by Randox employee Rachel Walls on behalf of her sister, Ursula McKenna, who will be running both the Dublin Marathon and Manchester half Marathon later this year in aid of the Cystic Fibrosis Trust.
Ursula McKenna has raised an impressive £3000 for the Cystic Fibrosis Trust and is set to continue her efforts in raising money for this great cause. Having run the London Marathon twice, with the last one completed on Sunday 24th April, her motivation stems from personal empathy of the condition;
‘Our cousin suffers from Cystic Fibrosis, and running a few marathons is easy compared to what he has to deal with on a daily basis’
Cystic Fibrosis is a genetic condition caused by a faulty gene that controls the movement of salt and water across the cell wall. This causes mucus to build up in the lungs and digestive tract, causing problems with breathing and digestion. An estimated 1 in 2,500 babies born in the UK have Cystic Fibrosis, with more than 2.5 million people in the UK carrying the faulty gene. Currently there is no cure for Cystic Fibrosis, however there are treatments to help manage the symptoms.
Ursula’s dedication to the cause is evident and this extends to her family through their help and support. The bake sale hosted by Rachel yesterday at Randox included scrumptious treats made by the family, and helped raise £308! In addition to hosting fundraising events, her brother also ran the New York Marathon in 2014 and will be joining Ursula in running the Dublin Marathon in October. Hoping to beat her previous completion times of 4:27 in her first marathon and 4:07 in her second marathon, Ursula aims to complete the Dublin Marathon in less than 4 hours. Good luck!
A lot happens between giving a patient sample and getting your results. Although you may never meet face-to-face, laboratory professionals play a very important role in health care. These professionals are ultimately responsible for conducting tests that provide results and information for detecting, diagnosing, treating and monitoring disease.
With the aim of celebrating and honouring medical laboratory professionals around the world who perform and interpret billions of laboratory tests every year, Lab Week has been taking place at the end of April each year for over 40 years.
Randox Quality Control would like to thank both the laboratory professionals who utilise our products and our own research & development laboratory staff who make our QC and EQA range the highest quality and most reliable available worldwide.
We are committed to revolutionising healthcare on a global scale.
Scientists at global healthcare company Randox, recently unveiled as the sponsors for The Grand National 2017 under the banner of Randox Health, today announced the company has been awarded an Innovate UK research award, for their pioneering work in the development of a diagnostic test for the detection of bladder cancer in haematuria patients.
The urine-based test is being developed in collaboration with The Belfast Trust and Queen’s University Belfast, and has been described by the project’s Lead Scientist at Randox, Dr Mark Ruddock, as the “holy grail” of diagnostic tests to stratify patients with haemeaturia (blood in the urine), who are at high risk of bladder cancer;
“Currently, all haematuria patients are ‘red-flagged’ as candidates for an invasive procedure called a cystoscopy (a camera inserted into the bladder), which is both embarrassing and uncomfortable for the patient. In comparison, the revolutionary Randox test is based on a simple urine sample so is non-invasive and much more comfortable for the patient.”
Considering less than 20% of patients with visible haematuria, and less than 5% with invisible haematuria are found to have bladder cancer, Dr Ruddock highlighted the urgent need for a test that can inform decisions for patients who present with haematuria;
“In the UK, over £33.5 million is spent each year managing patients with haematuria who are subsequently found not to have bladder cancer. As such, haematuria is a significant healthcare burden, which is only set to increase because of our aging population. Use of this new test will allow urology teams the opportunity to reduce the number of unnecessary cystoscopies carried out on patients identified as ‘low risk’, and stratify patients identified as ‘high risk’. This will result in significant healthcare savings, and an improvement in the waiting times for haematuria patients who do require diagnostic services ie. those patients deemed ‘high-risk’.”
Randox was successful in winning funding for phase one of the project, which has enabled an economic study to be carried out by The National Institute for Health Research Diagnostic Evidence Co-Operative Leeds who will investigate the economic benefits of the new diagnostic test for The National Health Service, and its role in the current patient care pathway. On successful completion of phase one, Randox will be eligible to apply for phase two funding.
Professor Peter Selby, Professor of Cancer Medicine at the University of Leeds, and Director of the NIHR Diagnostic Evidence Cooperative Leeds, said:
“Bladder cancer is a very important disease which can be life threatening but also in many patients it can generate great anxiety, frequent hospital visits and many investigations. The new approach being developed by Randox has the potential to save lives and improve the quality of lives of many people at risk of bladder cancer.”
“Diagnostic Classifier for risk stratification of haematuria patients” was selected by Innovate UK in the “Stratified Medicine: connecting the UK infrastructure” competition.
Global healthcare company Randox, recently unveiled as the main sponsor for the Grand National under the banner of Randox Health, is committed to supporting local grass roots horse racing, as this weekend it hosts the Point-to-Point Steeplechases at Crumlin, County Antrim, in association with the Killultagh, Old Rock and Chichester Hunt.
Point-to-Points are now firmly established in national hunt racing, with several champion horses starting their careers on the Irish Point-to-Point circuit.
Following the Randox Point-to-Point 2014, Classic Place was sold to Gigginstown House Stud, owned by Ryanair’s Michael O’Leary, who we all know to be the owner of The Crabbie’s Grand National 2016 winner, Rule The World.
Last year multiple All Ireland Champion Derek O’Connor registered a double, partnering Ballycross to victory for Templepatrick trainer Colin McKeever and leading local owner Wilson Dennison, followed by Chosen Dream at the fifth. O’Connor also recorded a brace of winners having scored with Sister Saragh at the first and Frost at the fifth.
But don’t worry if you’re not a racing enthusiast – the Randox Point-to-Point is the perfect day out for all the family. The increasingly popular event will host a unique Artisan village, showcasing a variety of food, drink and crafts stalls including, homemade jams, chutneys and sauces, ceramics, handmade chocolate and jewellery, woollen knits, handmade tea towels and tote bags, cakes, photography and much more!
Randox Managing Director, Dr Peter FitzGerald, highlighted the company’s equestrian heritage and is looking forward to both this year’s Point-to-Point, and next year’s Grand National:
“We are pleased to host the Point-to-Point with the Killultagh, Old Rock and Chichester Hunt, where champions are made. As a global company with firm links to our local heritage, we are proud to be involved with grass roots equestrian sports, which are part of the local community and sports scene. This history of being involved in equestrian events has naturally progressed to our sponsorship of the Grand National, and is fitting with our ambition. We look forward to this year’s two day Point-to-Point – where we might spot a future Randox Health Grand National winner!”
The Randox Point-to-Point will take place on Friday 22nd and Saturday 23rd of April, at Largy Road in Crumlin. The first race on Friday 22nd of April will start at 4pm; on Saturday 23rd of April, the first race takes place at 2pm.
General admission is £5 per person, with free entry for children under the age of 16.
Admission via the Laurelbank, Largy Road Crumlin, BT29 4RN.
Craft stalls are provided by North Down Crafts Collective and The Prince’s Trust charity.
For more information on the Randox Point-to-Point, email email@example.com
This week, Randox Testing Services opened the doors of its laboratory to BBC Newsline, and Donna Traynor, to offer an expert opinion on legal highs. Legal highs are mood-altering or stimulant substances whose sale is not banned by current legislation. They are made up of various chemical ingredients and replicate a similar user experience of illegal drugs such as cannabis, ecstasy and cocaine. They are extremely addictive and can have fatal side effects.
April 2016 marks the anniversary of one such case. The tragic passing of Adam Owens, a 17 year old boy who died after taking a legal high known as Sky brought this issue to the spotlight, and now one year on, the BBC want to know what is being done to tackle this issue.
The most difficult issue to combat with legal highs is that their chemical make-up is constantly being altered in order to get around legislation. As they keep changing it is difficult to create tests for these substances as they constantly evolve. Addressing this issue, Dr Mark Piper, Head of Toxicology at Randox Testing Services explained what is currently being done to try and counter this problem:
“We counter it here at Randox by continually developing new tests. In the past 12 months, Randox has developed over 115 new tests for new types of psychoactive substances.
These drugs are continually being developed and evolving into new types of substances which have previously fallen outside of the legislation, so it is a challenge for the likes of ourselves as drug testing laboratories to continually develop new tests to detect these substances.”
The prevalence of legal high use makes this an issue that cannot be avoided. Randox Testing Services are dedicated in their commitment to continually develop new tests in the fight against legal highs.
This week saw the publication of The Sunday Times Profit Track 100, and we are delighted to announce that Randox has been named at number 65 in the league table which ranks the 100 private UK companies with the fastest-growing profits over a three-year period.
Stuart Lisle, of BDO Accountants, featured Randox in his piece; ‘Innovation and trade make a good formula for expansion’, noting impressive findings that:
- Randox supplies 10% of the world’s cholesterol tests
- Our diagnostic products are used in 145 countries across the globe
Stuart Lisle commented;
“After outperforming most of our peers, Britain is entering a period of economic uncertainty: stock markets are volatile, growth in China is slowing, Europe’s recovery has stalled and, as the Bank of England governor Mark Carney noted in March, the possibility of Brexit is not helping. Our polling shows that 70% of mid-market companies think leaving the EU would make running their businesses harder but there are strong arguments on both sides of the debate.
Thankfully, while our politicians talk in Westminster, our mid-market companies are getting on with business, driving growth by innovating at home and trading overseas.
This year’s Profit Track 100 contains numerous examples. Just look at what Peter FitzGerald, founder of Randox Laboratories is achieving. From humble beginnings in his parents’ garden shed in County Antrim, Northern Ireland, he has developed the firm into one the supplies 10% of the world’s cholesterol tests as well as a range of other diagnostic instruments used in 145 countries…and it is one of 55 companies in this year’s Profit Track 100 that are growing by selling internationally.”
We would like to thank Stuart for recognising our success and innovation. We are extremely proud of how far the company has come – from humble beginnings over 34 years ago, to a company with more than 1400 employees of 44 nationalities, including 300 research scientists and engineers.
Dr Peter FitzGerald, Managing Director of Randox said:
“The growth that we have witnessed over the last 3 years principally enables us to further strengthen our infrastructure and increase the world leading research and development we are conducting – to achieve the earliest possible diagnosis of a very wide range of clinical conditions. We remain dedicated to saving lives and improving health worldwide, and reinvesting our profits helps ensure that we will realise our vision.”
The Profit Track 100 league table is compiled by Fast Track, the Oxford-based research and networking events firm.
Global healthcare company Randox, recently unveiled as the sponsors for the Grand National 2017 under the banner of Randox Health, today announced it has been awarded an Innovate UK Award, for their pioneering work in the development of a diagnostic test for Acute Myeloid Leukemia patients.
Randox’s award-winning test will enable the stratification of Acute Myeloid Leukemia (AML) patients, to determine patient response, before chemotherapeutic treatment. Currently, aggressive chemotherapy is given at diagnosis for the 2900 patients diagnosed with Acute Myeloid Leukemia every year in the UK, yet up to 40% of patients do not respond to this treatment due to the type of their cancer cells, and the patient’s genetic make-up.
The competition was therefore designed to promote the development of new diagnostic products and services for use in stratified medicine; in this case studying groups of leukemia patients to predict which treatments their cancers are likely to respond to.
Dr Cherith Reid, Project Manager for the AML Test at Randox, commented;
“As with any illness, it is important to select the best treatment and care for AML patients based on their diagnosis. The majority of AML patients are over 60 years old, and with the rise in the elderly population, increased prevalence of the disease is predicted. Currently, patients in this age range who are deemed fit for treatment are prescribed cytarabine chemotherapy, where the patient’s reaction to this drug is uninformed and is based on a trial-and-error approach. The information provided by our test will allow us to identify patients whose cancer is drug responsive, and treat them accordingly, possibly with lower doses of chemotherapy, reducing its severe side-effects. We want to assist clinicians in selecting the best treatment and care for patients as early as possible to improve patient outcomes.”
Phase one of the project includes an economic study to measure the health economic benefits for The National Health Service, conducted by The National Institute for Health Research Diagnostic Evidence Co-Operative London.
Professor George Hanna, NIHR DEC London Centre Director, commented;
“The stratification of patients within the NHS has been widely acknowledged as an important method for the efficient use of resources, as well as improving patient experience. New in vitro diagnostic tests that can classify patients in this way – such as the test being developed at Randox for Leukemia patients – personalise patient care to better inform treatment decisions which will hopefully lead to improved health outcomes and fewer side effects. This is particularly important for Leukemia patients who face the severe side effects of chemotherapy. Through the collaboration of Randox Laboratories and the NIHR Diagnostic Evidence Co-operative London, we have a unique opportunity to evaluate the adoption pathway of the new Randox AML technology to translate it to the bedside where it can best benefit patient care.”
“Determining Acute Myeloid Leukemia patient response to chemotherapeutic treatment” was selected by Innovate UK in the “Stratified Medicine: connecting the UK infrastructure” competition.
Pictured: Dr Cherith Reid
Parathyroid Hormone (PTH) is a hormone released by the parathyroid glands. It is often referred to as the parathormone and is often requested to help determine the cause of a low or high calcium concentration, helping to distinguish between parathyroid related and non-parathyroid related causes.
For health professionals
The new PTH Control has been designed with convenience in mind, providing laboratories with a true third party solution for the measurement of PTH. Our assayed liquid control has been developed with an extended open vial stability of 30 days and 2 year shelf life, reducing waste and ensuring consistency for this notoriously unstable assay.
Is your laboratory currently running PTH? Are you seeing shifts in QC results when you change reagent batch? If so, visit the new Acusera PTH Control product page for more information or register your interest.
More and more women in the United States are waiting until they’re older to start having children.
The number of births to women aged 45–49 rose 14% in 2013 from 2012, according to the Centers for Disease Control and Prevention’s National Vital Statistics Report. With this comes the responsibility by clinicians and laboratories to better assess those at risk of gestational diabetes and to aid better control of the condition for those who already have it. Quick and precise detection of risk of gestational diabetes and associated complications by clinical labs will provide women with the autonomy to take control of their maternal health.
Innovations in maternal health testing have meant that analysis such as adiponectin and enzymatic fructosamine are now available in automated biochemistry formats and with more accurate methodologies; allowing laboratories to assess gestational diabetes risk, and evaluate control of the condition with ease, speed and accuracy. Testing of such analytes have historically been non-routine and not easily accessible for clinical laboratories, and now with little adjustment within the laboratory, these can be added to the test menu allowing for detailed patient testing profiles.
Current innovations in the area of gestational diabetes testing will ultimately secure the health, both during and post-pregnancy, of mother and baby.
Randox Reagents are supporting World Health Day on April 7th 2016 this year!
The focus of this year’s World Health Day is on the fight against diabetes. It is essential to increase the awareness of this as a growing epidemic, let people know that diabetes is preventable and to help manage the effects of the illness in those already living with it.
What is diabetes?
Diabetes is a disease that occurs whenever the pancreas doesn’t produce enough insulin to properly regulate blood sugar levels. There are three main types of diabetes: type 1, type 2 and gestational.
Type 1 – People with this form of diabetes are unable to produce their own insulin and therefore must inject themselves with insulin.
Type 2 – This is the most common form of diabetes which occurs whenever a person can produce their own insulin but must put measures in place to control it. Type 2 diabetes accounts for 90% of diabetes cases worldwide.
Gestational – This form of diabetes affects women during pregnancy, when they develop high levels of glucose which insulin cannot bring under control.
The World Health Organisation (WHO) stated that in 2008, 347 million people had diabetes worldwide and in 2012, diabetes was the direct cause 1.5 million deaths.
Randox offer a range of high quality diabetes related diagnostic tests
It is crucial to raise awareness of diabetes to encourage people to get tested early, enabling them to put measures in place to avoid developing the illness, as well as ensuring complications do not occur. Randox are continuously developing the best quality diabetes-related diagnostic tests.
For diagnosis and monitoring
We offer tests for the diagnosis and monitoring of diabetes. These are Glucose, HbA1c and Fructosamine.
Diabetes can cause a number of complications such as chronic kidney disease, cardiovascular disease and even blindness. We offer a number of high quality tests which aid in monitoring these complications such as Albumin, Beta-2 Microglobulin, Cystatin C, D-3-Hydroxybutyrate, Microalbumin and Non-Esterified Fatty Acids (NEFA).
A related biomarker is Adiponectin, which can measure a patient’s visceral fat levels, the fat around the waist surrounding the internal organs. This can indicate heart disease risk, as well as insulin resistance.
With this broad diabetes testing panel, we will continue to support the aim to beat diabetes with World Health Day.
For more information on our diabetes tests view our diabetes page.
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- July 2014
- June 2014